Form 8-K - Current report:
SEC Accession No. 0000950170-22-013514
Filing Date
2022-07-29
Accepted
2022-07-29 17:01:45
Documents
12
Period of Report
2022-07-27
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 8-K acst-20220727.htm   iXBRL 8-K 53608
  Complete submission text file 0000950170-22-013514.txt   170801

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acst-20220727_lab.xml EX-101.LAB 13352
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acst-20220727_pre.xml EX-101.PRE 9851
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acst-20220727.xsd EX-101.SCH 2481
6 EXTRACTED XBRL INSTANCE DOCUMENT acst-20220727_htm.xml XML 4711
Mailing Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5
Business Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5 450-686-4555
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 221121707
SIC: 2834 Pharmaceutical Preparations